Pulling the Batch: Why Shilpa Medicare Recalled Over 27,000 Pemetrexed Vials Stateside

Shilpa Medicare Limited has initiated a voluntary nationwide recall across the United States for 27,923 vials of Pemetrexed injection, 500 mg/vial, single-dose vials. Disclosed through regulatory exchange filings on August 18, 2026, the recall action was formally triggered on July 29, 2026, after routine inspection routines flagged atypical discoloration in specific production lots. The US Food and Drug Administration (US FDA) subsequently classified the market withdrawal as a Class II recall at the hospital level. Company executives confirmed that the administrative and supply chain intervention affects four distinct product batches distributed across American healthcare markets.

Regulatory Classification and Recall Parameters

The voluntary recall encompasses a total of 27,923 single-dose vials of Pemetrexed for Injection (500 mg/vial), packaged in cartons. According to the enforcement classification report issued by the regulatory agency, the action falls under a Class II recall designation, which applies to situations where the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health effects is remote.

The primary trigger for the recall was the identification of atypical discoloration within the affected batches during ongoing quality assurance evaluations. Pemetrexed is a critical chemotherapy medication widely utilized in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Financial Assessment and Manufacturing Continuity

Addressing stakeholder concerns regarding market performance and revenue stability, Shilpa Medicare leadership stated that the company does not foresee any material financial impact on its overall operational results or balance sheet. Company representatives emphasized that no adverse event reports or medical complaints related to the affected batches have been received to date from patients, clinical institutions, or distributing partners. Furthermore, corporate filings clarify that the voluntary recall is strictly restricted to the four identified Pemetrexed batches and does not extend to any other pharmaceutical products manufactured or exported by the enterprise, ensuring that overall US supply continuity remains unaffected.

Official Sources Section

Recall specifications, classification data, and financial impact statements are documented according to regulatory enforcement reports published by the US Food and Drug Administration (US FDA) and official corporate disclosures filed by Shilpa Medicare Limited.

"According to officials, the voluntary recall is confined strictly to four specific batches due to atypical discoloration, with zero adverse health events reported, and the company expects no material impact on its financial position or ongoing operations."

Why It Matters

The practical implications of this Class II recall highlight the rigorous safety standards governing pharmaceutical imports in the United States while demonstrating proactive quality control by Indian drug manufacturers. For healthcare providers and clinical facilities, prompt voluntary action ensures patient safety without disrupting broader access to essential cancer therapeutics.

Key Facts at a Glance

• Product Involved: Pemetrexed for Injection, 500 mg/vial, single-dose vials.

• Quantity Recalled: 27,923 vials across 4 batches.

• Initiation Date: July 29, 2026.

• US FDA Classification: Class II recall (hospital level).

• Adverse Events: Zero adverse events reported.

• Financial Impact: Assessed by management as having no material impact on financial position or operations.

Frequently Asked Questions (FAQ)

Why did Shilpa Medicare recall Pemetrexed injection vials in the US?

The company initiated a voluntary recall after identifying atypical discoloration in specific product units during quality checks.

What is the US FDA classification of this recall?

The US FDA classified the action as a Class II recall, which applies at the hospital level.

How many vials are impacted by this recall action?

A total of 27,923 vials distributed across four specific batches are covered under the recall.

Will this recall affect Shilpa Medicare's other products or overall supply?

No. Company statements confirm that the recall does not impact other product lines or disrupt overall supply continuity.

Source: US Food and Drug Administration (US FDA), Shilpa Medicare Limited, National Stock Exchange of India (NSE)